Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Cholangiocarcinoma, Intrahepatic: early-phase trial registry

1 of 4 indexed Cholangiocarcinoma, Intrahepatic trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Cholangiocarcinoma, Intrahepatic: 4 US clinical trials tracked, 1 recruiting.

Cholangiocarcinoma, Intrahepatic is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is RedHill Biopharma Limited, running 1 of these trials.

Enrollment posture brief

Registry condition cholangiocarcinoma-intrahepatic

OPEN 1 | RECR 25% | LATE 0 | EARLY 1 | RANK #4115 | SPON 1

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Cholangiocarcinoma, Intr (th…25%
Open-enrollment share among volume-matched conditions near Cholangiocarcinoma, Intrahepatic

Cholangiocarcinoma, Intrahepatic lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cholangiocarcinoma, Intrahepatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cholangiocarcinoma, Intrahepatic is recruiting below its size-band peers.

    1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Cholangiocarcinoma, Intrahepatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Hydroxychloroquine Sulfate 200 MG Drug
1 trials
ABC294640 Drug
1 trials
LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma) Diagnostic test
1 trials
Percutaneous cholangiopancreatoscopy Procedure
1 trials
Liver Transplant Procedure
1 trials

US sites by state

Facility locations filed on Cholangiocarcinoma, Intrahepatic trials. A trial with sites in several states counts in each.

Utah 1 trials
Texas 1 trials
New Jersey 1 trials
Minnesota 1 trials
Maryland 1 trials
Georgia 1 trials
California 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cholangiocarcinoma, Intrahepatic page

4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Cholangiocarcinoma, Intrahepatic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • RedHill Biopharma Limited sponsors the most Cholangiocarcinoma, Intrahepatic trials on record, review their full trial history before evaluating a specific study. See RedHill Biopharma Limited's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cholangiocarcinoma, Intrahepatic condition card totals 4 registered trials; most-linked intervention Hydroxychloroquine Sulfate 200 MG; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.